Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 1.027
Filtrer
1.
Skin Res Technol ; 30(6): e13769, 2024 Jun.
Article de Anglais | MEDLINE | ID: mdl-38887837

RÉSUMÉ

BACKGROUND: The total glucoside of paeony (TGP) is recognized for its immunomodulatory properties and anti-inflammatory effects. This study evaluates the efficacy of TGP combined with oral mini-pulse therapy (OMP) and narrow-band ultraviolet B (NB-UVB) in treating active nonsegmental vitiligo (NSV). MATERIALS AND METHODS: The combination therapy was contrasted against those from a group treated solely with OMP and NB-UVB. Data from 62 patients undergoing TGP combination treatment and 55 without were analyzed over a 3-month period. After 6 months, the differences in recurrence rate were investigated by follow-up. RESULTS: The findings indicate that integrating TGP may yield superior outcomes compared to OMP + NB-UVB alone. Moreover, the patient's oxidative stress makers were significantly reduced after the treatment. The majority of patients in the TGP cohort exhibited enhanced skin pigmentation over the duration. Notably, no increase in side effects or recurrence was observed in this group. Especially, patients with vitiligo on their head and neck experienced pronounced improvements. CONCLUSION: The efficacy of the combination treatment group was better than that of the control group at 2 and 3 months, and there was no difference in recurrence rate and side effects, suggesting that TGP may continue to show efficacy in NSV for a longer period of time by reducing the level of oxidative stress, and is especially suitable for patients with head and neck lesions.


Sujet(s)
Glucosides , Paeonia , Traitement par ultraviolets , Vitiligo , Humains , Vitiligo/thérapie , Vitiligo/radiothérapie , Vitiligo/traitement médicamenteux , Femelle , Mâle , Adulte , Traitement par ultraviolets/méthodes , Études rétrospectives , Paeonia/composition chimique , Glucosides/administration et posologie , Glucosides/usage thérapeutique , Association thérapeutique/méthodes , Adulte d'âge moyen , Jeune adulte , Hormones corticosurrénaliennes/administration et posologie , Hormones corticosurrénaliennes/usage thérapeutique , Résultat thérapeutique , Administration par voie orale , Extraits de plantes/administration et posologie , Adolescent , Pigmentation de la peau/effets des médicaments et des substances chimiques , Pigmentation de la peau/effets des radiations
2.
Arch Dermatol Res ; 316(7): 358, 2024 Jun 08.
Article de Anglais | MEDLINE | ID: mdl-38850293

RÉSUMÉ

Follicular cell suspension (FCS) transplantation is a novel surgical method for treating resistant stable vitiligo, whereas mini punch grafting is an established effective method for treating stable vitiligo. The combination of FCS and mini punch grafting is a better strategy for the treatment of resistant stable vitiligo. The aim of the study was to evaluate the efficacy of follicular cell suspension, mini punch grafting, and a combination of both techniques in the treatment of stable vitiligo. This prospective comparative study was conducted on 48 patients with stable vitiligo. They were divided into three equal groups, including group A (treated with follicular cell suspension), group B (treated with mini punch grafting), and group C (treated with the combination of both techniques). All patients were followed-up for six months for the assessment of their therapeutic response regarding clinical outcomes. By comparing the data of the three studied groups, we found that the difference in the degree of re-pigmentation after one and three months of treatment was not significant. However, the progress of re-pigmentation was significantly different after six months of treatment among the three studied groups (P = 0.027). Specifically, re-pigmentation was significantly better in group C than in groups A and B (P = 0.037 and 0.017, respectively), but it was not significantly different between groups A and B.


Sujet(s)
Transplantation autologue , Vitiligo , Humains , Vitiligo/thérapie , Vitiligo/chirurgie , Femelle , Mâle , Adulte , Transplantation autologue/méthodes , Études prospectives , Résultat thérapeutique , Jeune adulte , Adulte d'âge moyen , Adolescent , Pigmentation de la peau , Follicule pileux/transplantation , Transplantation de peau/méthodes , Études de suivi
3.
Arch Dermatol Res ; 316(7): 350, 2024 Jun 08.
Article de Anglais | MEDLINE | ID: mdl-38850408

RÉSUMÉ

Loss and absence of melanocytes due to a number of factors is responsible for vitiligo; known to be the commonest disorder of pigmentation. The aim of the current work was to compare the efficacy and safety of excimer light with topical tacrolimus ointment 0.1% versus excimer light with topical bimatoprost gel 0.01% in treatment of facial vitiligo. The study was carried out on 48 patients presented with facial vitiligo. The patients were divided randomly using sealed envelope method into two groups (24 patients each). Group 1 were treated with excimer light plus topical tacrolimus ointment 0.1% and group 2 treated with excimer light plus topical bimatoprost gel 0.01%. Clinical improvement based on the quartile grading scale at the end of treatment did not show any statistically significant difference between groups. The majority of subjects in both groups experienced good to excellent improvement. Only 20.9% of patients in group 1 and 33.3% of subjects in group 2 achieved less than 50% repigmentation (p = 0.889). Our study demonstrated that 0.01% topical bimatoprost gel in combination with excimer light is considered safe and effective as treatment of nonsegmental facial vitiligo with comparable results to 0.1% tacrolimus.


Sujet(s)
Bimatoprost , Tacrolimus , Vitiligo , Humains , Vitiligo/traitement médicamenteux , Vitiligo/thérapie , Vitiligo/diagnostic , Tacrolimus/administration et posologie , Bimatoprost/administration et posologie , Femelle , Mâle , Adulte , Résultat thérapeutique , Jeune adulte , Adolescent , Adulte d'âge moyen , Lasers à excimères/usage thérapeutique , Administration par voie topique , Pigmentation de la peau/effets des médicaments et des substances chimiques , Pigmentation de la peau/effets des radiations , Face , Administration par voie cutanée , Enfant , Association thérapeutique/méthodes , Immunosuppresseurs/administration et posologie , Immunosuppresseurs/usage thérapeutique
5.
Arch Dermatol Res ; 316(7): 399, 2024 Jun 15.
Article de Anglais | MEDLINE | ID: mdl-38878236

RÉSUMÉ

Vitiligo is considered an autoimmune disease, and its treatment is challenging. We assessed and compared the effect of fractional erbium:yttrium-aluminum-garnet (Er:YAG) laser-assisted delivery of platelet-rich plasma versus microneedling (Mn) with platelet-rich plasma (PRP) in enhancing skin repigmentation in localized stable vitiligo patients. In total, 40 patients with localized stable vitiligo were selected in a random manner into two similar groups (20 each). Group (A) was subjected to fractional Er:YAG laser combined with platelet-rich plasma and Group (B) was subjected to microneedling combined with platelet-rich plasma. The procedure was repeated every 2 weeks for up to 6 months. Each individual was assessed clinically utilizing Vitiligo Area Scoring Index (VASI). Fractional Er:YAG + PRP group achieved better pigmentation100% (excellent 30%, very good 15%, good 30% and satisfactory 25%) which is comparable to Mn + PRP where 80% of cases demonstrate repigmentation (20% very good, 10% good and 50% mild). When comparing the VASI scores for both groups after therapy to the baseline VASI, there was a statistically significant decrease [p = 0.001 for group(A) and 0.003 for group(B)]. Regarding the treatment side effects, there was significantly (p = 0.048) side effects among cases treated with microneedling group(B) (25%) than those fractional Er:Yag laser therapy group(A) (5%). Both forms of therapy demonstrated induction of repigmentation of vitiligo, but fractional Er:YAG laser efficacy is greater when combined with platelet-rich plasma.Clinical trials.gov identifier: NCT05511493.


Sujet(s)
Lasers à solide , Aiguilles , Plasma riche en plaquettes , Pigmentation de la peau , Vitiligo , Humains , Vitiligo/thérapie , Vitiligo/radiothérapie , Vitiligo/diagnostic , Lasers à solide/usage thérapeutique , Femelle , Mâle , Adulte , Résultat thérapeutique , Pigmentation de la peau/effets des radiations , Jeune adulte , Adulte d'âge moyen , Adolescent , Puncture sèche/méthodes , Puncture sèche/instrumentation , Association thérapeutique/méthodes ,
6.
Adv Ther ; 41(7): 2890-2906, 2024 Jul.
Article de Anglais | MEDLINE | ID: mdl-38802636

RÉSUMÉ

INTRODUCTION: Vitiligo, a chronic autoimmune skin depigmentation disease with an unpredictable course, has been associated with several comorbid autoimmune and psychological conditions. Our current understanding of vitiligo burden and management in the real world is limited. This real-world analysis presents data on vitiligo epidemiology, comorbidities, and treatment of patients in Israel. METHODS: This retrospective study analyzed data from the Maccabi Health Services database. Prevalent patients with vitiligo in 2021 were matched to patients in the general population on the basis of age group, gender, and socioeconomic status. Patient demographics, vitiligo incidence and prevalence, comorbidities, and treatment patterns are reported. Data are presented as percentages, mean, median, P values, and standard mean differences (SMD). RESULTS: In this analysis, 11,412 patients with vitiligo were matched to patients from the general population. Incidence and prevalence rates increased over time from 2005 to 2021. Compared to the general population, patients with vitiligo were more likely to have an immune-mediated comorbidity (29.7% vs 18.4% [P < 0.001; SMD 0.27]) or psychological comorbidity (18.7% vs 15.9% [P < 0.001; SMD 0.07]). Comorbidities included atopic dermatitis (patients with vitiligo vs general population 12.5% vs 8.4%), psoriasis (5.8% vs 3.6%), Hashimoto's thyroiditis (2.9% vs 1.1%), alopecia areata (2.2% vs 0.9%), depression (10.8% vs 9.5%), and sleep disorder/insomnia (5.9% vs 4.4%). Only 74.8% of all patients with vitiligo had ever received treatment, with topical corticosteroids (51.5%) and calcineurin inhibitors (36.5%) most commonly prescribed. At the end of 2021, 83.7% of patients were untreated. CONCLUSION: Patients with vitiligo are more likely to have various immune-related and psychological comorbidities, highlighting the significant impact of the condition on well-being. Nearly a quarter of patients had never received treatment, with many receiving only topical treatments, and medication persistence was low. This highlights the lack of adequate treatment in this population and the need for more effective management options.


Sujet(s)
Comorbidité , Vitiligo , Humains , Vitiligo/épidémiologie , Vitiligo/thérapie , Vitiligo/psychologie , Mâle , Femelle , Études rétrospectives , Adulte , Israël/épidémiologie , Adulte d'âge moyen , Prévalence , Incidence , Jeune adulte , Adolescent , Enfant , Sujet âgé , Enfant d'âge préscolaire
7.
Photodermatol Photoimmunol Photomed ; 40(3): e12974, 2024 May.
Article de Anglais | MEDLINE | ID: mdl-38728444

RÉSUMÉ

BACKGROUND/PURPOSE: Existing phototherapies are ineffective for treating patients with vitiligo with complete leukotrichia. We compared the efficacy of reverse perilesional irradiation, during which only the lesional areas are covered, with conventional narrowband ultraviolet B (NB-UVB) home phototherapy for repigmentation of non-segmental vitiligo in patients with complete leukotrichia. METHODS: This was a 12-week, open-label, double-arm, multicenter clinical trial, with a total of 121 patients with non-segmental vitiligo who were randomly divided into two groups (both received topical tacrolimus): the conventional NB-UVB irradiation (CI) and reverse perilesional NB-UVB irradiation (RI) groups. RESULTS: A statistically significant difference in improvement from baseline was observed in the RI group compared with the findings in the CI group (-30.8% ± 11.8% vs. -25.5% ± 11.05%, respectively [p = .010]; pair-wise comparison p = .900 at week 4, p = .104 at week 8, and p = .010 at week 12). At week 12, the average percentage change from baseline of leukotrichia in the irradiation area significantly decreased from 100% to 82.2% ± 13.65% in the RI group, and from 100% to 88.7% ± 9.64% in the CI group (p = .027). Adverse events were minor, including desquamation, dryness, erythema, and blisters. No severe or lasting side effects were observed during the study. CONCLUSION: RI mediated better repigmentation of vitiligo with complete leukotrichia than CI.


Sujet(s)
Traitement par ultraviolets , Vitiligo , Humains , Vitiligo/thérapie , Vitiligo/radiothérapie , Femelle , Mâle , Adulte , Traitement par ultraviolets/méthodes , Pigmentation de la peau , Adulte d'âge moyen , Adolescent , Tacrolimus/usage thérapeutique , Tacrolimus/administration et posologie
9.
Exp Dermatol ; 33(5): e15091, 2024 May.
Article de Anglais | MEDLINE | ID: mdl-38711220

RÉSUMÉ

KIT ligand and its associated receptor KIT serve as a master regulatory system for both melanocytes and mast cells controlling survival, migration, proliferation and activation. Blockade of this pathway results in cell depletion, while overactivation leads to mastocytosis or melanoma. Expression defects are associated with pigmentary and mast cell disorders. KIT ligand regulation is complex but efficient targeting of this system would be of significant benefit to those suffering from melanocytic or mast cell disorders. Herein, we review the known associations of this pathway with cutaneous diseases and the regulators of this system both in skin and in the more well-studied germ cell system. Exogenous agents modulating this pathway will also be presented. Ultimately, we will review potential therapeutic opportunities to help our patients with melanocytic and mast cell disease processes potentially including vitiligo, hair greying, melasma, urticaria, mastocytosis and melanoma.


Sujet(s)
Mastocytes , Mastocytose , Mélanocytes , Protéines proto-oncogènes c-kit , Facteur de croissance des cellules souches , Humains , Facteur de croissance des cellules souches/métabolisme , Mélanocytes/métabolisme , Mastocytes/métabolisme , Mastocytose/traitement médicamenteux , Mastocytose/métabolisme , Protéines proto-oncogènes c-kit/métabolisme , Mélanome/métabolisme , Mélanome/traitement médicamenteux , Vitiligo/métabolisme , Vitiligo/traitement médicamenteux , Vitiligo/thérapie , Troubles de la pigmentation/traitement médicamenteux , Tumeurs cutanées/métabolisme , Tumeurs cutanées/traitement médicamenteux , Animaux
10.
J Coll Physicians Surg Pak ; 34(5): 514-517, 2024 May.
Article de Anglais | MEDLINE | ID: mdl-38720208

RÉSUMÉ

OBJECTIVE: To assess the efficacy of microneedling in combination with topical tacrolimus ointment 0.1% versus topical tacrolimus ointment 0.1% for treatment of refractory stable vitiligo. STUDY DESIGN: Comparative cross-sectional study. Place and Duration of the Study: Department of Dermatology, PNS Shifa, Karachi, Pakistan, from December 2022 to May 2023. METHODOLOGY: The study included 30 clinically diagnosed individuals of either gender who had refractory symptoms and aged between 20 and 60 years. For every patient, two comparable lesions on two comparable limb regions were selected. Group A (right side) received treatment with both topical tacrolimus ointment 0.1% twice daily in addition to microneedling every two weeks, whereas, Group B (left side) was treated with topical tacrolimus ointment 0.1% only. Every lesion was investigated as a separate entity. Both groups were subsequently observed for a further six months. RESULTS: When topical tacrolimus ointment 0.1% was combined with microneedling, the total re-pigmentation rate was substantially higher than the usage of tacrolimus ointment 0.1% alone. Fifty-three percent of lesions treated with topical tacrolimus ointment 0.1% alone and 76.7% of lesions treated with microneedling in conjunction with it showed a good-to-excellent response. No adverse negative effects were noted. During the follow-up period, no problems or recurrences were noted. CONCLUSION: Tacrolimus ointment combined with microneedling is a successful treatment for refractory stable vitiligo. KEY WORDS: Dermapen, Depigmentation, Microneedling, Tacrolimus ointment, Vitiligo.


Sujet(s)
Immunosuppresseurs , Onguents , Tacrolimus , Vitiligo , Humains , Vitiligo/thérapie , Vitiligo/traitement médicamenteux , Tacrolimus/administration et posologie , Tacrolimus/usage thérapeutique , Femelle , Mâle , Adulte , Adulte d'âge moyen , Études transversales , Immunosuppresseurs/administration et posologie , Immunosuppresseurs/usage thérapeutique , Résultat thérapeutique , Association thérapeutique , Aiguilles , Jeune adulte , Administration par voie cutanée , Administration par voie topique , Puncture sèche/méthodes ,
11.
Photodermatol Photoimmunol Photomed ; 40(3): e12972, 2024 May.
Article de Anglais | MEDLINE | ID: mdl-38752300

RÉSUMÉ

BACKGROUND: In previous studies, the 308-nm light-emitting diode (LED) has been proven safe and effective for treating vitiligo. However, direct comparisons between the 308-nm LED and 308-nm excimer lamp (308-nm MEL) for the treatment of vitiligo are lacking. OBJECTIVE: To compare the efficacy of the 308-nm LED and 308-nm MEL for treating nonsegmental stable vitiligo. PATIENTS AND METHODS: This randomized controlled trial was conducted between January 2018 and August 2023. Enrolled patients were randomly assigned to either the 308-nm LED or the 308-nm MEL groups, both receiving 16 treatment sessions. Adverse events that occurred during the treatment were documented. RESULTS: In total, 269 stable vitiligo patches from 174 patients completed the study. A total of 131 lesions were included in the 308-nm LED group, and 138 lesions were included in the 308-nm MEL group. After 16 treatment sessions, 38.17% of the vitiligo patches in the 308-nm LED group achieved repigmentation of at least 50% versus 38.41% in the 308-nm MEL group. The two devices exhibited similar results in terms of efficacy for a repigmentation of at least 50% (p = .968). The incidence of adverse effects with the two phototherapy devices was comparable (p = .522). CONCLUSIONS: Treatment of vitiligo with the 308-nm LED had a similar efficacy rate to the 308-nm MEL, and the incidence of adverse effects was comparable between the two devices.


Sujet(s)
Vitiligo , Humains , Vitiligo/radiothérapie , Vitiligo/thérapie , Femelle , Mâle , Adulte , Adulte d'âge moyen , Adolescent , Lasers à excimères/usage thérapeutique , Lasers à excimères/effets indésirables , Jeune adulte , Enfant
12.
Noise Health ; 26(120): 37-43, 2024.
Article de Anglais | MEDLINE | ID: mdl-38570309

RÉSUMÉ

OBJECTIVE: Noise is a kind of perceived public nuisance that is closely related to people's subjective feelings and lives. This study explores the clinical application effect of comprehensive noise reduction technology in outpatients with vitiligo. METHODS: A total of 76 patients with vitiligo were selected in the Department of Dermatology at Baoding No. 2 Central Hospital from January 2020 to January 2021, as the control group (CG), receiving 5S management mode, and 80 patients with vitiligo from February 2021 to October 2022 were selected as the study group (SG), receiving comprehensive noise reduction technology combined with the 5S management mode for this retrospective study. The effects of different management modes on these patients were observed. RESULTS: SG had higher nursing quality scores in service attitude, service initiative, communication skills, environmental management and item management and overtly a lower noise level than CG (all P < 0.001). The Hamilton Anxiety Scale (HAMA) scores of the two groups at the end of treatment were significantly lower than those on admission (P < 0.05), with SG showing a lower score than CG (P < 0.001). Correlation analysis showed that noise levels and HAMA scores had a positive correlation (r = 0.423, P < 0.001). Patients with negative feelings about medical treatment caused by various noise sources in SG were obviously less than those in CG (P < 0.05). Both the groups had a statistical difference in overall satisfaction (P < 0.05). CONCLUSION: The investigation and data analysis demonstrated that comprehensive noise reduction in outpatients with vitiligo had a considerable effect. This technology can standardise the behaviour of medical staff, enhance nursing quality, reduce noise levels and alleviate patients' anxiety and improve their satisfaction. It has great benefits for the outpatient environment and patients.


Sujet(s)
Vitiligo , Humains , Études rétrospectives , Vitiligo/thérapie , Patients en consultation externe , Enquêtes et questionnaires , Satisfaction des patients
13.
Photodermatol Photoimmunol Photomed ; 40(3): e12968, 2024 May.
Article de Anglais | MEDLINE | ID: mdl-38632705

RÉSUMÉ

BACKGROUND: Vitiligo is characterized by depigmented patches resulting from loss of melanocytes. Phototherapy has emerged as a prominent treatment option for vitiligo, utilizing various light modalities to induce disease stability and repigmentation. AIMS AND METHODS: This narrative review aims to explore the clinical applications and molecular mechanisms of phototherapy in vitiligo. RESULTS AND DISCUSSION: The review evaluates existing literature on phototherapy for vitiligo, analyzing studies on hospital-based and home-based phototherapy, as well as outcomes related to stabilization and repigmentation. Narrowband ultra-violet B, that is, NBUVB remains the most commonly employed, studied and effective phototherapy modality for vitiligo. Special attention is given to assessing different types of lamps, dosimetry, published guidelines, and the utilization of targeted phototherapy modalities. Additionally, the integration of phototherapy with other treatment modalities, including its use as a depigmenting therapy in generalized/universal vitiligo, is discussed. Screening for anti-nuclear antibodies and tailoring approaches for non-photo-adapters are also examined. CONCLUSION: In conclusion, this review provides a comprehensive overview of phototherapy for vitiligo treatment. It underscores the evolving landscape of phototherapy and offers insights into optimizing therapeutic outcomes and addressing the challenges ahead. By integrating clinical evidence with molecular understanding, phototherapy emerges as a valuable therapeutic option for managing vitiligo, with potential for further advancements in the field.


Sujet(s)
Traitement par ultraviolets , Vitiligo , Humains , Vitiligo/thérapie , Traitement par ultraviolets/méthodes , Photothérapie , Mélanocytes , Résultat thérapeutique
14.
Arch Dermatol Res ; 316(5): 126, 2024 Apr 23.
Article de Anglais | MEDLINE | ID: mdl-38652183

RÉSUMÉ

Vitiligo is characterized by skin depigmentation, which can lead to profound psychological effects and decreased quality of life, especially for those with skin of color. Individuals with vitiligo may utilize complementary and alternative medicine (CAM) due to limited treatment options with varying efficacy.An anonymous, multiple-choice, cross-sectional questionnaire was distributed to participants with vitiligo in the United States through online forums. Data on disease characteristics, use of prescription medications, use of topical therapies, supplements, and diets, and perceptions of CAM were collected.In total, 625 respondents completed the survey. Overall, 32.5% of participants (203/625) have tried CAM. Commonly reported CAM include supplements of vitamin D (57.7%, 116/203), vitamin B12 (46.3%, 93/203), vitamin C (27.4%, 55/203), topical Nigella sativa oil (26.4%, 53/203), oral omega-3 fatty acids (24.9%, 50/203), folic acid (22.9%, 46/203), and vitamin E (22.9%, 46/203). Frequently cited reasons for CAM use include desire to try "new" (40.4%, 82/203) or "more natural" (26.6%, 54/203) therapies, "frustration with conventional medicine" (24.6%, 50/203), and fear of "adverse side effects of conventional medicine" (23.6%, 48/203). Non-White participants were more likely than their White counterparts to report CAM use and have more positive perceptions of CAM therapies. Less than half (43.3%, 88/203) of CAM users reported that they disclosed their use of CAM with their physician.Dermatologists should be mindful of CAM and ask patients about their use. Further investigation of the role of CAM as adjuvant therapy for vitiligo is warranted to better advise patients.


Sujet(s)
Thérapies complémentaires , Compléments alimentaires , Vitiligo , Adolescent , Adulte , Sujet âgé , Femelle , Humains , Mâle , Adulte d'âge moyen , Jeune adulte , Thérapies complémentaires/statistiques et données numériques , Thérapies complémentaires/méthodes , Études transversales , Compléments alimentaires/statistiques et données numériques , Qualité de vie , Pigmentation de la peau , Enquêtes et questionnaires/statistiques et données numériques , États-Unis , Vitiligo/thérapie , Vitiligo/psychologie ,
15.
Photodermatol Photoimmunol Photomed ; 40(3): e12970, 2024 May.
Article de Anglais | MEDLINE | ID: mdl-38685665

RÉSUMÉ

OBJECTIVE: Both piperine and a 308-nm excimer laser have significant curative effects on vitiligo. This study mainly explored the molecular mechanism of a 308-nm excimer combined with piperine in regulating melanocyte proliferation. METHODS: Epidermal melanocytes were cultured in piperine solution, and the cells were irradiated by an XTRAC excimer laser treatment system at 308-nm output monochromatic light. Quantitative real-time polymerase chain reaction (qRT-PCR) and Western blot were for detecting the expression levels of genes or proteins. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) and Transwell method was for assessing cell viability and migration capacity. The content of melanin was also detected. RESULTS: The combination of the 308-nm excimer laser and piperine enhanced the cell proliferation, migration, and melanin production of melanocytes and upregulated the level of miR-328, and restraint of miR-328 reversed the influence of the 308-nm excimer laser and piperine. Secreted frizzled-related protein 1 (SFRP1) is a direct target gene of miR-328, and miR-328 can inhibit the expression of SFRP1 and elevate the protein level of the Wnt/ß-catenin signaling pathway. CONCLUSION: The 308-nm excimer laser combined with piperine may be more efficient than piperine alone in the remedy of vitiligo, and the miR-328/SFRP1 and Wnt/ß-catenin pathways are participated in the proliferation, migration, and melanin synthesis of melanocytes.


Sujet(s)
Benzodioxoles , Mouvement cellulaire , Prolifération cellulaire , Mélanines , Pipéridines , Humains , Alcaloïdes/pharmacologie , Benzodioxoles/pharmacologie , Mouvement cellulaire/effets des médicaments et des substances chimiques , Prolifération cellulaire/effets des médicaments et des substances chimiques , Mélanines/biosynthèse , Mélanocytes/métabolisme , Mélanocytes/effets des médicaments et des substances chimiques , Protéines membranaires/métabolisme , Protéines membranaires/génétique , microARN/génétique , microARN/métabolisme , Pipéridines/pharmacologie , Amides gras polyinsaturés N-alkylés/pharmacologie , Protéines et peptides de signalisation intercellulaire/génétique , Protéines et peptides de signalisation intercellulaire/métabolisme , Lasers , Vitiligo/traitement médicamenteux , Vitiligo/thérapie
16.
Eur J Dermatol ; 34(1): 13-17, 2024 Feb 01.
Article de Anglais | MEDLINE | ID: mdl-38557453

RÉSUMÉ

Vitiligo is a human pigmentary disorder characterized by autoimmune destruction of mature melanocytes in the skin. In addition to studies on the inflammatory component of the disease, current treatments tend to involve stimulation of local melanocyte stem cells or transplantation of functional melanocytes from uninjured areas, however, in some cases of extensive depigmentation, only a few healthy cells can be obtained. This review discusses examples in the literature of the use of different sources of autologous stem and somatic cells in order to obtain melanocyte progenitors or mature melanocytes, and compares the strategy of stem cell differentiation with that of somatic cell reprogramming. More specifically, this review illustrates the capability of stem cells to differentiate from dental pulp, bone marrow, and adipose tissue; the reprogramming of pluripotent cells and the transdifferentiation of fibroblasts and keratinocytes. Each of these approaches is capable of producing fully functional melanocytes, but all have advantages and disadvantages. Finally, the relevance for potential clinical application is discussed, along with the risks associated with each strategy and the major current barriers to their use.


Sujet(s)
Vitiligo , Humains , Vitiligo/thérapie , Mélanocytes , Peau , Kératinocytes , Différenciation cellulaire
17.
J Cosmet Dermatol ; 23(7): 2320-2327, 2024 Jul.
Article de Anglais | MEDLINE | ID: mdl-38465786

RÉSUMÉ

BACKGROUND: Vitiligo, an autoimmune skin disorder linked to hormonal and genetic factors, results in reduced pigmentation due to a gradual decline in melanocyte activity. This systematic review delves into the role of dietary intervention and nutrition in managing vitiligo. METHODS: A comprehensive search on PubMed, Google Scholar, and European PMC identified 214 studies, with 14 meeting inclusion criteria post-screening. The selected studies primarily explored the impact of dietary supplements on disease activity. RESULTS: Heavy metal exposure, specifically Cd, Pb, and Hg, indicated potential links to heightened reactive oxygen species and vitiligo development. Conflicting evidence emerged regarding the role of trace minerals (Zn and Cu), with some studies suggesting deficiencies and others proposing excesses in vitiligo patients. Vitamins with anti-inflammatory properties like vitamin C, D, and B12, along with antioxidants, were investigated for their potential in repigmentation strategies. Additionally, polyunsaturated fatty acids (PUFAs), especially in varying types of fat consumption, were implicated. Emphasizing the need to reduce reliance on pharmacological and phototherapy interventions, the review uncovers novel roles for dietary supplements as adjuncts or flare reducers. CONCLUSION: While dietary interventions cannot be thought of as a standalone therapy, they still make a case for being used as adjuncts. Large scale clinical trials are warranted to establish strong evidence and protocols, and might also help reduce the dependency on pharmacological methods, which come with their adverse effect profiles.


Sujet(s)
Compléments alimentaires , Vitiligo , Humains , Vitiligo/thérapie , Vitiligo/diétothérapie , Régime alimentaire/effets indésirables , Antioxydants/administration et posologie , Vitamines/administration et posologie , État nutritionnel , Pigmentation de la peau , Oligoéléments/administration et posologie , Acides gras insaturés/administration et posologie
18.
Stem Cells Transl Med ; 13(5): 415-424, 2024 May 14.
Article de Anglais | MEDLINE | ID: mdl-38513284

RÉSUMÉ

BACKGROUND: Surgical intervention is the main therapy for refractory vitiligo. We developed a modified autologous cultured epithelial grafting (ACEG) technique for vitiligo treatment. Between January 2015 and June 2019, a total of 726 patients with vitiligo underwent ACEG in China, with patient characteristics and clinical factors being meticulously documented. Using a generalized linear mixed model, we were able to assess the association between these characteristics and the repigmentation rate. RESULTS: ACEG demonstrated a total efficacy rate of 82.81% (1754/2118) in treating 726 patients, with a higher repigmentation rate of 64.87% compared to conventional surgery at 52.69%. Notably, ACEG showed a better response in treating segmental vitiligo, lesions on lower limbs, age ≤ 18, and stable period > 3 years. A keratinocyte:melanocyte ratio below 25 was found to be advantageous too. Single-cell RNA sequencing analysis revealed an increase in melanocyte count and 2 subclusters of keratinocytes after ACEG, which remained higher in repigmented sites even after 1 year. CONCLUSIONS: ACEG is a promising therapy for refractory vitiligo. Patient age, clinical type, lesion site, and stability before surgery influence repigmentation in ACEG. The mechanism of repigmentation after ACEG treatment is likely not confined to the restoration of melanocyte populations. It may also involve an increase in the number of keratinocytes that support melanocyte function within the affected area. These keratinocytes may aid the post-transplant survival and function of melanocytes by secreting cytokines and extracellular matrix components. TRIAL REGISTRATION: registered with Chictr.org.cn (ChiCTR2100051405).


Sujet(s)
Transplantation autologue , Vitiligo , Humains , Vitiligo/thérapie , Mâle , Femelle , Études rétrospectives , Transplantation autologue/méthodes , Adulte , Adolescent , Jeune adulte , Adulte d'âge moyen , Mélanocytes/transplantation , Enfant , Kératinocytes/transplantation , Cellules cultivées , Épithélium
19.
J Cosmet Dermatol ; 23(6): 2220-2230, 2024 Jun.
Article de Anglais | MEDLINE | ID: mdl-38470079

RÉSUMÉ

INTRODUCTION: Vitiligo is a skin pigmentation disorder caused by the selective degradation of melanocytes. This study investigates the therapeutic effects of microneedling with and without N-acetylcysteine (NAC) in patients with persistent and limited vitiligo. METHOD: This research employed a clinical trial design with double-blind randomization. Individuals affected by vitiligo and seeking treatment at Rasool Akram Medical Complex were divided into two separate treatment groups. In the intervention group, 24 affected areas underwent meso-microneedling using 5% NAC ampoules over six sessions, in addition to the application of 4.7% NAC cream once daily on the specified area. Conversely, the control group, consisting of 22 lesions, underwent microneedling using distilled water during six sessions. The severity of lesions and the extent of repigmentation were gauged using the Modified VETI Score. Assessment of treatment efficacy was determined through both physician evaluations and patient feedback. RESULTS: Twenty patients with a mean age of 36.4 years were recruited. The mean percentage of lesions and their intensity were significantly improved 2 weeks after the third session and 1 month after the end of the treatment (p < 0.01). There was no statistically significant difference between the intervention and control groups. Gender, age, family history, duration of disease, duration of disease stability, and history of hypothyroidism had no statistically significant relationship with patients' treatment outcomes (p > 0.05). CONCLUSION: Microneedling with or without the application of NAC appears to be an effective treatment option for persistent vitiligo lesions. However, despite the higher improvement rate with the application of NAC, the difference was not significant.


Sujet(s)
Acétylcystéine , Vitiligo , Humains , Vitiligo/thérapie , Vitiligo/traitement médicamenteux , Acétylcystéine/administration et posologie , Acétylcystéine/effets indésirables , Acétylcystéine/usage thérapeutique , Méthode en double aveugle , Femelle , Adulte , Mâle , Adulte d'âge moyen , Résultat thérapeutique , Association thérapeutique/effets indésirables , Association thérapeutique/méthodes , Jeune adulte , Indice de gravité de la maladie , Puncture sèche/effets indésirables , Puncture sèche/méthodes , Aiguilles/effets indésirables , Adolescent , Pigmentation de la peau/effets des médicaments et des substances chimiques
20.
Photodermatol Photoimmunol Photomed ; 40(2): e12958, 2024 Mar.
Article de Anglais | MEDLINE | ID: mdl-38489300

RÉSUMÉ

BACKGROUND/PURPOSE: Vitiligo is a depigmenting disorder that affects up to 2% of the population. Due to the relatively high prevalence of this disease and its psychological impact on patients, decisions concerning treatment can be difficult. As patients increasingly seek health information online, the caliber of online health information (OHI) becomes crucial in patients' decisions regarding their care. We aimed to assess the quality and readability of OHI regarding phototherapy in the management of vitiligo. METHODS: Similar to previously published studies assessing OHI, we used 5 medical search terms as a proxy for online searches made by patients. Results for each search term were assessed using an enhanced DISCERN analysis, Health On the Net code of conduct (HONcode) accreditation guidelines, and several readability indices. The DISCERN analysis is a validated questionnaire used to assess the quality of OHI, while HONcode accreditation is a marker of site reliability. RESULTS: Of the 500 websites evaluated, 174 were HONcode-accredited (35%). Mean DISCERN scores for all websites were 58.9% and 51.7% for website reliability and treatment sections, respectively. Additionally, 0/130 websites analyzed for readability scored at the NIH-recommended sixth-grade reading level. CONCLUSION: These analyses shed light on the shortcomings of OHI regarding phototherapy treatment for vitiligo, which could exacerbate disparities for patients who are already at higher risk of worse health outcomes.


Sujet(s)
Information en santé des consommateurs , Vitiligo , Humains , Compréhension , Vitiligo/thérapie , Reproductibilité des résultats , Photothérapie , Internet
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...